Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Sep;22(3):421–425. doi: 10.1128/aac.22.3.421

Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

E de Clercq, Z X Zhang, I S Sim
PMCID: PMC183760  PMID: 7137983

Abstract

(E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU) was examined for its ability to increase the survival rate of mice infected intracerebrally with herpes simplex virus type 1 (strain KOS). BVDU was administered orally (through the drinking water), intraperitoneally, or subcutaneously at doses ranging from 40 to 400 mg/kg per day, starting 0, 2, 4, or 6 days postinfection. Regardless of the route of administration, BVDU effected a significant reduction in the mortality rate of mice infected with herpes simplex virus type 1 if treatment was initiated shortly after virus infection, i.e., day 0 or 2 (or day 4, if BVDU was administered subcutaneously) postinfection, at a dosage of 80 mg/kg per day or higher. Similar beneficial effects were noted with orally administered BVDU in mice inoculated intraperitoneally or intranasally with herpes simplex virus type 1. These findings establish the therapeutic efficacy of BVDU in the systemic treatment of herpes simplex virus type 1 encephalitis in mice.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Chen M. S., Lee J. J., De Clercq E., Prusoff W. H. Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells. J Biol Chem. 1982 Jan 25;257(2):603–606. [PubMed] [Google Scholar]
  2. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheng Y. C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol. 1981 Jul;20(1):230–233. [PubMed] [Google Scholar]
  4. Cho C. T., Feng K. K., Brahmacupta N. Synergistic antiviral effects of adenine arabinoside and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis. 1976 Feb;133(2):157–167. doi: 10.1093/infdis/133.2.157. [DOI] [PubMed] [Google Scholar]
  5. Cho C. T., Feng K. K. Combined effects of acycloguanosine and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis. 1980 Sep;142(3):451–451. doi: 10.1093/infdis/142.3.451. [DOI] [PubMed] [Google Scholar]
  6. Clough D. W., Parkhurst J. R. Experimental herpes simplex virus type 1 encephalitis: treatment with 5-trifluoromethyl-2'-deoxyuridine. Antimicrob Agents Chemother. 1977 Feb;11(2):307–311. doi: 10.1128/aac.11.2.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Davis W. B., Oakes J. E., Taylor J. A. Effect of treatment with 5-ethyl-2'-deoxyuridine on herpes simplex virus encephalitis in normal and immunosuppressed mice. Antimicrob Agents Chemother. 1978 Nov;14(5):743–748. doi: 10.1128/aac.14.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2947–2951. doi: 10.1073/pnas.76.6.2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  10. De Clercq E., Zhen-Xi Zhang Differential effects of E-5-(2-bromovinyl)-2'-deoxyuridine on infections with herpes simplex virus type 1 and type 2 in hairless mice. J Infect Dis. 1982 Jan;145(1):130–130. doi: 10.1093/infdis/145.1.130. [DOI] [PubMed] [Google Scholar]
  11. De Clercq E., Zhen-Xi Z., Descamps J., Huygen K. E-5-(2-bromovinyl)-2'-deoxyuridine vs. interferon in the systemic treatment of infection with herpes simplex virus of athymic nude mice. J Infect Dis. 1981 Jun;143(6):846–852. doi: 10.1093/infdis/143.6.846. [DOI] [PubMed] [Google Scholar]
  12. Descamps J., De Clercq E., Barr P. J., Jones A. S., Walker R. T., Torrence P. F., Shugar D. Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. Antimicrob Agents Chemother. 1979 Nov;16(5):680–682. doi: 10.1128/aac.16.5.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Griffith J. F., Fitzwilliam J. F., Casagrande S., Butler S. R. Experimental herpes simplex virus encephalitis: Comparative effects of treatment with cytosine arabinoside and adenine arabinoside. J Infect Dis. 1975 Nov;132(5):506–510. doi: 10.1093/infdis/132.5.506. [DOI] [PubMed] [Google Scholar]
  14. Kern E. R., Glasgow L. A., Overall J. C., Jr, Reno J. M., Boezi J. A. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrob Agents Chemother. 1978 Dec;14(6):817–823. doi: 10.1128/aac.14.6.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. J Infect Dis. 1973 Sep;128(3):290–299. doi: 10.1093/infdis/128.3.290. [DOI] [PubMed] [Google Scholar]
  16. Machida H., Ichikawa M., Kuninaka A., Saneyoshi M., Yoshino H. Effect of treatment with 1-beta-D-arabinofuranosylthymine of experimental encephalitis induced by herpes simplex virus in mice. Antimicrob Agents Chemother. 1980 Feb;17(2):109–114. doi: 10.1128/aac.17.2.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maudgal P. C., De Clercq E., Descamps J., Missotten L., De Somer P., Busson R., Vanderhaeghe H., Verhelst G., Walker R. T., Jones A. S. (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis. Antimicrob Agents Chemother. 1980 Jan;17(1):8–12. doi: 10.1128/aac.17.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maudgal P. C., De Clercq E., Descamps J., Missotten L., Wijnhoven J. Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine. Arch Ophthalmol. 1982 Apr;100(4):653–656. doi: 10.1001/archopht.1982.01030030655027. [DOI] [PubMed] [Google Scholar]
  19. Park N. H., Pavan-Langston D., McLean S. L., Albert D. M. Therapy of experimental herpes simplex encephalitis with aciclovir in mice. Antimicrob Agents Chemother. 1979 Jun;15(6):775–779. doi: 10.1128/aac.15.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Plummer G., Ingerson A. P. Iododeoxyuridine and herpesviral encephalitis: lack of inhibitory action against low-grade viral replication. Antimicrob Agents Chemother. 1974 Jun;5(6):672–673. doi: 10.1128/aac.5.6.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  22. Sidwell R. W., Allen L. B., Khare G. P., Huffman J. H., Witkowski J. T., Simon L. N., Robins R. K. Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother. 1973 Feb;3(2):242–246. doi: 10.1128/aac.3.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sloan B. J., Miller F. A., McLean I. W., Jr Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine. Antimicrob Agents Chemother. 1973 Jan;3(1):74–80. doi: 10.1128/aac.3.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. de Clercq E., Descamps J., de Somer P., Barr P. J., Jones A. S., Walker R. T. Pharmacokinetics of E-5-(2-bromovinyl)-2'-deoxyuridine in mice. Antimicrob Agents Chemother. 1979 Aug;16(2):234–236. doi: 10.1128/aac.16.2.234. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES